For the tens of millions of adults who carry genetic or lifestyle risk factors for Alzheimer's disease, the question of whether dementia is truly preventable — not just delayed — has profound personal stakes. A perspective piece published in JAMA takes stock of a half-century of effort to answer that question, and the picture it paints is both encouraging and sobering.
The article traces the arc from early epidemiological observations linking cardiovascular risk factors to dementia, through the failed amyloid-clearing drug trials of the 2000s and 2010s, to the more recent successes with anti-amyloid immunotherapies such as lecanemab and donanemab in prodromal and early-stage populations. Central to the discussion is the conceptual shift from treating symptomatic Alzheimer's to intervening during the long preclinical window — the 15-to-20-year period when amyloid and tau pathology accumulate silently before cognitive decline emerges. The perspective also addresses multidomain lifestyle interventions, pointing to trials examining blood pressure control, physical activity, and metabolic health as modifiable pathways that may independently reduce dementia incidence.
What makes this framing analytically valuable is its implicit tension: pharmacological progress has finally produced agents that measurably reduce amyloid burden and slow clinical progression, yet the effect sizes remain modest and come with meaningful risks, particularly amyloid-related imaging abnormalities (ARIA). This positions lifestyle and vascular risk reduction not as consolation prizes but as complementary and potentially synergistic strategies. The perspective arrives at a moment when prevention trials are beginning to enroll cognitively normal adults identified by biomarker screening — a methodological leap that could transform Alzheimer's into a condition managed decades before symptoms appear. For health-conscious adults, the most actionable signal emerging from this body of work remains cardiovascular health in midlife: blood pressure, glucose regulation, and physical activity appear to be among the most robust modifiable levers identified across 50 years of research.
